Breaking World Pharma News

Bristol-Myers Squibb and Pfizer announce charitable donations of more than $1 million to support cardiovascular education

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced charitable donations totaling more than $1 million to be granted between 2014 and 2016 to seven nonprofit organizations that support patients with cardiovascular disease.

Read more...

Merck to acquire Sigma-Aldrich to enhance position in attractive life science industry

Merck KGaAMerck, a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, and Sigma-Aldrich today announced that they have entered into a definitive agreement under which Merck will acquire Sigma-Aldrich for $17.0 billion (€13.1 billion), establishing one of the leading players in the $130 billion global life science industry.

Read more...

Single dose of antidepressant changes the brain

A single dose of antidepressant is enough to produce dramatic changes in the functional architecture of the human brain. Brain scans taken of people before and after an acute dose of a commonly prescribed SSRI (serotonin reuptake inhibitor) reveal changes in connectivity within three hours, say researchers who report their observations in the Cell Press journal Current Biology on September 18.

Read more...

Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse?

High school biology taught us that we inherit certain traits from our parents that are pre-determined. But what if you could change how these genes play out by taking certain drugs or better yet, just changing your diet? That's exactly what a team of researchers at the Boston University School of Medicine (BUSM) have proposed through their research of epigenetics research.

Read more...

What's more effective: Generic or brand-name statins?

Statins are the most frequently prescribed drugs in the United States and are effective in reducing cardiovascular events. However, evidence suggests that patients do not always take these medications as prescribed and may not receive their full benefit. Researchers from Brigham and Women's Hospital (BWH), Harvard Medical School and CVS Health investigated whether the use of generic versus brand-name statins can play a role in medication adherence and whether or not this leads to improved health outcomes.

Read more...

AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer's disease

AstraZenecaAstraZeneca and Eli Lilly and Company (Lilly) today announced an agreement to jointly develop and commercialise AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.

Read more...

Researcher develops and proves effectiveness of new drug for spinal muscular atrophy

According to recent studies, approximately one out of every 40 individuals in the United States is a carrier of the gene responsible for spinal muscular atrophy (SMA), a neurodegenerative disease that causes muscles to weaken over time. Now, researchers at the University of Missouri have made a recent breakthrough with the development of a new compound found to be highly effective in animal models of the disease.

Read more...

World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]